Home / Health / Biogen seeks US approval for potential Alzheimer's drug, stock jumps

Biogen seeks US approval for potential Alzheimer's drug, stock jumps

The number of people in the United States living with Alzheimer's, the most common form of dementia, is expected to triple to nearly 14 million by 2050 without effective treatments

drug, medicine, drugs, pharma, pharmaceutical

Premium

Biogen shares were up nearly 5 per cent at $281.34 in afternoon trading on the Nasdaq

3 min read Last Updated : Jul 09 2020 | 1:07 AM IST

Biogen Inc said on Wednesday it submitted an application seeking US approval of its closely watched Alzheimer's drug, as the company aims to be the first to bring a treatment to market that can alter the course of the mind-wasting disease.

Biogen shares were up nearly 5 per cent at $281.34 in afternoon trading on the Nasdaq.

The number of people in the United States living with Alzheimer's, the most common form of dementia, is expected to triple to nearly 14 million by 2050 without effective treatments, according to the US Centers for Disease Control and Prevention.

If approved, Biogen's aducanumab would be

Topics : Biogen Alzheimer's Nasdaq USFDA

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in